CURCUMIN-LOADED MULTI-VALENT LIGANDS CONJUGATED-NANOPARTICLES FOR ANTI-INFLAMMATORY ACTIVITY
Keywords:
Curcumin, Multi-valent ligands, Anti-inflammation, Polymeric nanoparticles, cIBR, cLABLAbstract
Objective: The present study aims to develop curcumin-loaded muti-valent ligands conjugated-nanoparticlesfor targeted cell and study the biological activities including anti-inflammatory activity and kinetic cellular uptake.
Methods: Curcumin encapsulated PLGA nanoparticles were formulated by solvent displacement method. The cIBR and cLABL peptides were conjugated on the surface of PLGA nanoparticles using carbodiimide reaction to produce curcumin encapsulated cIBR-cLABL-nanoparticles (cIBR-cLABL-NPs). The expression of LFA-1 and ICAM-1 on the membrane of U937 cells were determined by flow cytometry. Kinetic binding and internalization profile of cIBR-cLABL-NPs and untargeted nanoparticles were also investigated by flow cytometry. Safety profile on PBMC and cytotoxicity profile on U937 cells were evaluated using the MTT assay. Anti-inflammatory activity was determined using aprotein denaturation method.
Results: The densities of cIBR and cLABL peptide on the surface of PLGA nanoparticles were 22.0±4.4 and 19.6±2.8 pmol/cm2, respectively. The particle size and total surface area of PLGA were 256.1 nm and 0.038 m2/g. The result showed that U937 cells expressed both LFA-1 and ICAM-1 proteins on their membranes indicating the possibility to use U937 cells as a targeted cell. According to the kinetic binding and internalization profiles, the cellular uptake of cIBR-cLABL-NPs was significantly higher than that of untargeted-NPs at all-time points indicating the specific uptake of cIBR-cLABL-NPs to target cell. Moreover, the rate of binding and internalization interpreted by the slope of linear regression of cIBR-cLABL-NPs was more rapid than that of untargeted-NPs. The MTT assay revealed the safety on human PBMC of cIBR-cLABL-NPs. The IC50 of free curcumin and curcumin-loaded cIBR-cLABL-NPs were 0.13 and 2.27 μg/ml, respectively. Protein denaturation assay presented the concentration dependenceinhibition of protein denaturation by curcumin and cIBR-cLABL-NPs indicating anti-inflammatory activities of free curcumin and encapsulated curcumin.
Conclusion: cIBR-cLABL-nanoparicles increased the quantity of binding, rate of binding, and the internalization by target cells with safety profile on human PBMC. Moreover, the biological activity of encapsulating agent was maintained. Therefore, it could be used as a drug delivery system for encapsulating anti-infalmmatory agents.
Â
Downloads
References
Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem 2008;114(2):127-49.
Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009;29(10):3867-75.
Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliver Rev 2000;41(2):147-62.
Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 2005;26(29):5898-906.
Chittasupho C. Multivalent ligand: design principle for targeted therapeutic delivery approach. Ther Delivery 2012;3(10):1171-87.
Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Controlled Release 2006;114(3):277-87.
Anderson M, Siahaan T. Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery. Pharm Res 2003;20(10):1523-32.
Anderson M, Yakovleva T, Hu Y, Siahaan T. Inhibition of ICAM-1/lFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg Med Chem Lett 2004;14(6):1399-402.
Chittasupho C, Manikwar P, Krise J, Siahaan T, Berkland C. cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Mol Pharm 2009;7(1):146-55.
Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. PLGA nanoparticle−peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjugate Chem 2007;19(1):145-52.
G rsoy R, Siahaan T. Binding and internalization of an ICAM 1 peptide by the surface receptors of T cells. J Pept Res 1999;53(4):414-21.
Chittasupho C, Xie S, Baoum A, Yakovleva T, Siahaan T, Berkland C. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 2009;37(2):141-50.
Phongpradist R, Chittasupho C, Okonogi S, Siahaan T, Anuchapreeda S, Ampasavate C, et al. LFA-1 on leukemic cells as a target for therapy or drug delivery. Curr Pharm Des 2010;16(21):2321-30.
Chittasupho C, Shannon L, Siahaan TJ, Vines CM, Berkland C. Nanoparticles targeting dendritic cell surface molecules effectively block T cell conjugation and shift response. ACS Nano 2011;5(3):1693-702.
Mizushima Y, Kobayashi M. Interaction of antiâ€inflammatory drugs with serum proteins, especially with some biologically active proteins. J Pharm Pharmacol 1968;20(3):169-73.
Lub M, van Kooyk Y, Figdor C. Ins and outs of LFA-1. Immunol Today 1995;16(10):479-83.
Kilic MA, Ozlu E, Calis S. A novel protein-based anticancer drug encapsulating nanosphere: Apoferritin-doxorubicin complex. J Biomed Nanotechnol 2012;8(3):508-14.
Warren RA, Green FA, Enns CA. Saturation of the endocytic pathway for the transferrin receptor does not affect the endocytosis of the epidermal growth factor receptor. J Biol Chem 1997;272(4):2116.
Phongpradist R, Chittasupho C, Intasai N, Siahaan TJ, Berkland CJ, Charoenkwan P, et al. Biodegradable nanoparticles surface modification techniques with cIBR peptide targeting to LFA-1 expressing leukemic cells. J Nanotechnol Eng Med 2012;3(4):041005.
Opie EL. On the relation of necrosis and inflammation to denaturation of proteins. J Exp Med 1962;115(3):597-608.
Chandra S, Chatterjee P, Dey P, Bhattacharya S. Evaluation of in vitro anti-inflammatory activity of coffee against the denaturation of protein. Asian Pac J Trop Biomed 2012;2(1):S178-S80.
Williams L, Rosner H, Conrad J, Moller W, Beifuss U, Chiba K, et al. Selected secondary metabolites from phytolaccaceae and their biological/pharmaceutical significance. Recent Res Dev Phytochem 2002;6:13-68.
Kawabata T, Packer L. α-Lipoate can protect against glycation of serum albumin, but not low-density lipoprotein. Biochem Biophys Res Commun 1994;203(1):99-104.
Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011;3(3):1377-97.
Fernández-Carballido A, Puebla P, Herrero-Vanrell R, Pastoriza P. Radiosterilisation of indomethacin PLGA/PEG-derivative microspheres: Protective effects of low temperature during gamma-irradiation. Int J Pharm 2006;313(1–2):129-35.
Munin A, Edwards-Lévy F. Encapsulation of natural polyphenolic compounds; a review. Pharm 2011;3(4):793-829.